Others titles

  • Post-Approval Studies
  • Medical Device Post-Approval Studies

Keywords

  • CDRH and Applicants
  • CDRH’s Post-Approval Studies
  • Post-Approval Studies
  • PAS
  • Post-Approval Device

FDA Post Approval Studies Database

The Post-Approval Studies (PAS) Database identifies the reporting status of PAS studies based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH’s effort to ensure that all PAS commitments are fulfilled in a timely manner.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Standard End User License Agreement (“EULA”) applies to customers of John Snow Labs Inc. (as defined below), using any product of John Snow Labs Inc. on John Snow Labs Marketplace as defined below (hereinafter referred to “you”) and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading, installing, and/or using (as applicable) any Product of John Snow Labs (as defined below), you automatically agree to be bound by, and use our Products in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE PURCHASING, INSTALLING OR USING OUR PRODUCTS MADE AVAILABLE ON JOHN SNOW LABS MARKETPLACE.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of our Products after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“John Snow Labs Data Library” means a data library located at https://www.johnsnowlabs.com;

“Products” means products and services of John Snow Labs that you download and use from listings in John Snow Labs Data Library;

Important Notice

By installing and using our Products, you acknowledge that the use of the Products can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use the Products for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Products can be used by an individual, business or other legal entity, or both. If you are entering into this EULA, or using the Products, on behalf of a company or other legal entity, you represent that you have the authority to bind such entity to this EULA, in which case “you” shall refer to such entity.

In the event you have entered into a separate written agreement with John Snow Labs regarding the Products that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all.

Your Access and Use

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, license to install, access to, modify, and use of, the Products worldwide (subject to applicable export laws) during the term of this EULA (as described below) solely for research, private study and personal use of Products.

This license is personal to you, and you may not resell our Products, permit other users access to our Products through your account. Your right to use our Products is limited by all terms and conditions set forth in this EULA.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Products, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Products are protected by applicable intellectual property laws, including United States copyright law and international treaties.

Except for the foregoing license, you have no other rights in the Products and you may not modify, edit, copy, reproduce, create derivative works of, reverse engineer, alter, enhance or in any way exploit the Products in any manner. If you breach any of this EULA, the above license will terminate automatically.

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of the Products. You are responsible for end users’ use of your content and the Products. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and the Products by such end user. We do not provide any support or services to end users unless we have a separate agreement with you or an end user obligating us to provide such support or services.

Restrictions

You will access or use our Products solely via John Snow Labs Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. reproduce, modify, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of any of our Products or its technological features or measures;
  2. rent, lease, sell, resell, loan, distribute, or sublicense access to any of our Products;
  3. circumvent or disable any security or technological features or measures of our Products;
  4. use our intellectual property rights without our express prior written authorization;
  5. use our Products for more than one trial period, unless the trial period is extended by John Snow Labs’ prior written permit;
  6. use our Products with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of the Products;
  7. store, copy, modify, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on our Products (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  8. use any automated tool (e.g., robots, spiders) to access or use our Products, or to store, copy, modify, distribute, or resell any Content;
  9. circumvent or disable any rights management, usage rules, or other security features of our Products;
  10. use our Products in a manner that overburdens, or that threatens the integrity, performance, or availability of, our Products; or
  11. remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Fees and Taxes

Your use of the Products is subject to our fees. All fees are given on our website https://www.johnsnowlabs.com. Except as set forth in this EULA, the fees are non-refundable. We are entitled to revise our fees from time to time.

The fees exclude any federal, state or local taxes, VAT, GST, or similar taxes. You are responsible for identification and payment of all taxes as required by applicable law.

Term and Termination

This EULA will become effective as of the date of your order of Products and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use our Products, if you or your end user’s use of the Products:

  1. is in breach of this EULA;
  2. poses a security risk to our Products;
  3. could adversely impact our systems, the Products or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use our Products, if you fail to perform your payment obligations, or you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

We may also suspend or terminate your right to use our Products without any reason upon a relevant 30 days’ written notice to you and will refund the unused fees pre-paid by you for access to the Products for the affected time period (if any). Where your access is suspended or terminated by the breach of this EULA or applicable laws, John Snow Labs will will not provide, or be liable for, any refund.

You will cease use of the Products during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Support

If applicable to your Product, John Snow Labs will provide you with the support services. If you use a trial access, support services are excluded. Under this EULA, our support services exclude any installation, training, maintenance services (including any error corrections, bug fixes, or new releases), technical assistance, consulting services, or other services of any kind. Such services are provided at John Snow Labs’ discretion.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Access to our Products

We do not provide you with the equipment to access our Products. You are responsible for all fees charged by third parties related to your access and use of our Products (e.g., charges by Internet service providers).

You are responsible for monitoring your use of the Products, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of the Products for auditing purposes.

You also certify that you are legally permitted to use the Products, and take full responsibility for the selection and use of the Products. This EULA is void where prohibited by law, and the right to use the Products is revoked in such jurisdictions. John Snow Labs makes no claim that the Products may be lawfully used outside of the United States. If you use the Products from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Our Products may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using our Products (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using our Products, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

The Products, including software, is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to the Products or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on our Products are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of our Products, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs and may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in our Products are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF THE PRODUCTS IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of the Products; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of the Products will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Products. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about our Products or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

CDRH’s Post-Approval Studies Program ensures that methodologies are well-designed and conducted effectively, efficiently and in the least burdensome manner. In 2005, the Division of Epidemiology (DEPI) in CDRH’s Office of Surveillance and Biometrics (OSB) assumed responsibility for overseeing the program. Along with OSB, other CDRH offices including the Office of Device Evaluation (ODE), and the Office of In-Vitro Diagnostics and Radiological Health (OIR), share PAS Program responsibilities for design, tracking, oversight, and review of these mandated studies. Post-approval studies (PAS) are conditions of device approval. A sponsor’s failure to comply with any post-approval requirement may be grounds for withdrawing approval.

CDRH has established the Post-Approval Studies Database to share general information regarding each PAS ordered since January 1, 2005, provides the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant’s current reporting status for each submission due. The database refreshes every Sunday with any new or revised information on study protocol parameters (e.g., patient population), overall study status, or information related to the review of data from interim or final reports.

About this Dataset

Data Info

Date Created

2005

Last Modified

2020-08-10

Version

2021-06-26

Update Frequency

Irregular

Temporal Coverage

1991-09 to 2020-08

Spatial Coverage

United States

Source

John Snow Labs; Food and Drug Administration (FDA);

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

CDRH and Applicants, CDRH’s Post-Approval Studies, Post-Approval Studies, PAS, Post-Approval Device

Other Titles

Post-Approval Studies, Medical Device Post-Approval Studies

Data Fields

Name Description Type Constraints
Application_NumberPAS Application Numberstringrequired : 1
Applicant_NameThe Applicant Namestringrequired : 1
Device_NameMedical Device Namestringrequired : 1
Medical_SpecialtyMedical Specialty of the Medical Devicestringrequired : 1
Date_PMA_ApprovedPremarket-Approval (PMA) Approved Datedaterequired : 1
Study_NameMedical Device Study Namestringrequired : 1
Protocol_Accepted_DateThe Protocol Accepted Datedate-
Current_Protocol_Accepted_DateThe Current Protocol Accepted Datedate-
Study_StatusThe status of the study determined by the FDA After the review of a supplement with a protocol or of an interim or final report.string-
Study_Progress_ReasonMedical device study progress reasonstring-
Study_DesignMedical device study designstring-
Is_Study_Involve_Follow_Up_Of_Premarket_CohortStudy involve follow-up of premarket cohortboolean-
Data_SourceThe Data sourcestringenum : Array ( [0] => Admin Database [1] => External Registry [2] => New Data Collection [3] => Other Data Source [4] => Sponsor Registry )
Comparison_GroupMedical device comparison groupstring-
Analysis_TypeMedical device analysis typestringenum : Array ( [0] => Analytical [1] => Descriptive ) maxLength : 11
Study_PopulationMedical device study populationstring-
Study_Design_DescriptionMedical device study design descriptionstring-
Study_Population_DescriptionMedical device study population descriptionstring-
Sample_SizeStudy sample sizestring-
Data_CollectionData collectionstring-
Followup_Visits_and_Length_of_FollowupFollowup Visits and Length of Followupstring-
Actual_Number_of_Patients_EnrolledActual Number of Patients Enrolledstring-
Actual_Number_of_Sites_EnrolledActual Number of Sites Enrolledstring-
Patient_Followup_RatePatient Followup Ratestring-
Final_Safety_FindingsFinal medical device safety findingsstring-
Final_Effectiveness_FindingsFinal effectiveness findingsstring-
Study_Strengths_and_WeaknessesMedical device study strengths and weaknessesstring-
Recommendations_for_Labeling_ChangesRecommendations for medical device labeling changesstring-
Interim_Safety_InformationSafety information of the interimstring-

Data Preview

Application NumberApplicant NameDevice NameMedical SpecialtyDate PMA ApprovedStudy NameProtocol Accepted DateCurrent Protocol Accepted DateStudy StatusStudy Progress ReasonStudy DesignIs Study Involve Follow Up Of Premarket CohortData SourceComparison GroupAnalysis TypeStudy PopulationStudy Design DescriptionStudy Population DescriptionSample SizeData CollectionFollowup Visits and Length of FollowupActual Number of Patients EnrolledActual Number of Sites EnrolledPatient Followup RateFinal Safety FindingsFinal Effectiveness FindingsStudy Strengths and WeaknessesRecommendations for Labeling ChangesInterim Safety Information
P170038/ PAS001AbbottCentriMag Circulatory Support SystemCardiovascular2019-12-06CentriMag FTW PAS2020-05-22Study PendingProspective Cohort StudyFalseNew Data CollectionObjective Performance CriterionAnalyticalTransit. Adolescent B (as adults) : 18-21 yrs; Adult: >21
P160030/ PAS001ABBOTT DIABETES CARE INC.Freestyle Libre Flash Glucose Monitoring SystemClinical Chemistry2017-09-27FreeStyle Libre Flash Glucose Monitoring 2017-12-082018-09-25Progress AdequateProspective Cohort StudyFalseNew Data CollectionDevice Subjects Serve as Own ControlAnalyticalTransit. Adolescent B (as adults) : 18-21 yrs; Adult: >21This is a one-year prospective; multi-center; nonrandomized; single-arm; post-approval study of the FreeStyle Libre 14 Day Flash CGM intended to characterize the safety of the device when used in people with type 1 and type 2 diabetes non-adjunctively in ages 18 years and up.Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using the FreeStyle Libre 14 Day Flash for 6 months (intervention phase). Subjects will maintain a diary/log book of adverse events during each phase. Assessment ofadverse events will occur via self-reporting at each monthly visit and/or phone call. Subjects will also complete a Quality of Life questionnaire at the completion of the control phase and the intervention phase. Up to 920 subjects will be enrolled in up to 10 sites to obtain at least 736subjects who complete the study. The purpose of this study is to characterize the safety of the Libre 14 Day Flash Glucose Monitoring System when used in the intended use population. Adult (18 years of age and up) with type 1 and type 2 diabetes that meet the inclusion/exclusion criteria will be studied.The device is investigational in ages 4-17 years. The 4-17 year age group will also be studied under an approved IDE G170269/S001.Inclusion Criteria:Subjects will be considered for enrollment in the study if they meet all of the following criteria:1. Subject must be at least 18 years of age2. Subject must have a diagnosis of type 1 or type 2 diabetes mellitus3. Subject is currently using SMBG for managing their diabetes4. Subject must be able to read and understand English and/or Spanish5. In the investigators opinion; the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol6. Subject must have access to an internet connected for uploading data from the blood glucose meter and FreeStyle Libre system.7. Subject must be willing and able to provide written signed and dated informed consent and assent when appropriate.Exclusion Criteria:1. Subject is a member of the Site Staff2. Subject is currently using or has previously used a continuous glucose monitoring system for managing their diabetes3. Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.4. Subject is pregnant at the time of enrollment5. Subject is on dialysis at the time of enrollment6. Subject has concomitant medical condition which; in the opinion of the investigator; could interfere with the study or present a risk to thesafety or welfare of the subject or study staff7. Subject currently participating in another clinical trial8. Subject is unsuitable for participation due to any other cause as determined by the investigator.Up to 920 subjects will be enrolled Primary Endpoint:An analysis of the rate of severe hypoglycemic andhyperglycemic events will compare the intervention phase(approximate days 180 to 365) to the control phase(approximate days 1-180).Secondary Endpoints:BG frequency in the control and intervention phasesScan frequency in the intervention phaseChange in HbA1cDTSQ (Quality of Life Questionnaire).Follow-up visits are scheduled throughout the study period for 12 months.
P150004/ PAS001Abbott MedicalAxium Neurostimulator SystemNeurology2016-02-11F/U Axium Neurostimulator System (FANS)2016-05-262017-07-26Progress AdequateProspective Cohort StudyFalseNew Data CollectionObjective Performance CriterionAnalyticalAdult: >21The FANS PAS is a prospective; multicenter; single arm; observational post-approval study to be conducted at up to 45 centers in the United States in order to demonstrate continued safety and effectiveness of the Axium Neurostimulator System or the Proclaim DRG Neurostimulator System. The primary objective of the FANS PAS is to demonstrate that the proportion of serious adverse events (SAEs) at 12 months for subjects who receive a permanent implant is lower than a pre-specified performance goal. Secondary objectives of the FANS PAS are to evaluate change in overall pain intensity; change in physical function and change in quality of life over the study period.A maximum of 426 adult subjects with moderate to severe chronic; intractable pain of the lower limbs due to CRPS types I and II will undergo a trial of the neurostimulator system at up to 45 study sites in the United States.Inclusion Criteria: Male or female between the ages of 22 and 75 years. Moderate to severe chronic intractable pain of the lower limbs resulting from Complex Regional Pain Syndrome (CRPS) types I or II. Baseline VAS score of > 60 mm for overall pain at the time of the baseline assessment. Willing and able to comply with the study requirements. Able to provide written informed consent.Exclusion criteria: Subject has an active implantable medical device including but not limited to cardiac pacemakers and cardiac defibrillators. Subject is currently involved in medically-related litigation; including workers compensation. Subject has a life expectancy of less than one year. Subject is pregnant or of child bearing potential and not using adequate contraception as determined by the investigator. Subject has; or plans to have; a spinal cord stimulation system or infusion pump system implanted. Subject has; or plans to have; a peripheral nerve stimulation system (PNS) or peripheral nerve field stimulation system (PNfS) implanted. Subject is considered a poor surgical or study candidate; which may include; but is not limited to the following: any medical; social; or psychological problem that could complicate the implant procedure and/or recovery from the implant procedure or could complicate the required procedures and evaluations of the study in the judgment of the investigator.The sample size required to reject the null hypothesis for the primary endpoint at the 5% significance level with 80% power assuming a 12-month SAE rate of 10.5% is 287 subjects receiving the permanent Axium or Proclaim DRG IPG. Assuming an attrition rate of 25% from trial to permanent Axium or Proclaim DRG IPG implant; and an attrition rate of 10% from permanent implant to 12-month follow-up; a total of 426 (=287/0.9/0.75)subjects will be implanted with a trial system. The target number of subjects for permanent Axium or Proclaim DRG IPG implants is 319; and the target number of subjects for the primary endpoint analysis is 287.Primary EndpointThe primary endpoint is the 12-month SAE rate for subjects receiving the permanent DRG IPG.Secondary Endpoints Percent change from baseline to 12 months post-permanent implant for overall pain intensity measured using the Visual Analog Scale (VAS)Change from baseline to 12 months post-permanent implant for physical function measured using the PROMIS-29 Profile Change from baseline to 12 months post-permanent implant for quality of life measured using the PROMIS Global Health ScaleDescriptive EndpointsSafety Proportion of subjects with device; procedure or stimulation related SAEs and non-SAEs among subjects who receive the permanent implant Proportion of subjects who have AEs related to the trial implant procedure among subjects who fail the trial neurostimulator phase Summary of procedure-related SAEs and non-SAEs by implanter experienceEffectiveness Change from baseline to 1; 3; and 6 months post permanent implant for overall pain intensity measured using the Visual Analog Scale (VAS) Change from baseline to 1; 3; and 6 months post permanent implant for physical function measured using the PROMIS-29 Profile Change from baseline to 1; 3; and 6 months post-permanent implant for quality of life measured using the PROMIS Global Health Scale Change from baseline to 1; 3; 6 and 12 months post-permanent implant for neuropathic pain measured using the Neuropathic Pain Scale (NPS) Change from baseline to 1; 3; 6 and 12 months post-permanent implant for sleep disturbance; anxiety; depression; fatigue; ability to participate in social roles and activities; paininterference and pain intensity measured using the PROMIS-29 Profile Patient Global Impression of Change (PGIC) at 1; 3; 6 and 12 months post-permanent implantAdditional DataAll descriptive endpoints above will be examined at 18 and 24 months for all subjects with evaluable data for those study visits. Additional data; including but not limited to; percentage of subjects achieving at least a 30% and 50% pain reduction; demographics; paresthesia coverage and intensity; subject satisfaction; programming parameters; implant procedure information; and system information may be compiled.up to 24 months
P040040/ PAS001Abbott MedicalAMPLATZER MUSCULAR VSD OCCLUDERCardiovascular2007-09-075 year long term (IDE)2007-09-072007-09-07TerminatedOther reasonProspective Cohort StudyTrueSponsor RegistryConcurrent ControlDescriptiveChild: 2-12 yrs; Adolescent: 13-18 yrs; Transit. Adolescent B (as adults) : 18-21 yrs; Adult: >21This study will provide long-term follow-up of forty-three subjects from the premarket cohort that have been designated as High Risk.This device is indicated for use in patients with a complex VSD of significant size to warrant closure (large volume left to right shunt; pulmonary hypertension and/or clinical symptoms of congestive heart failure) who are considered to be at high risk for standard transatrial or transarterial surgical closure based on anatomical conditions and/or based on overall medical condition.43 patients; 21 sitesSafety endpoints include adverse events. Annual office visits were required out to 5 years.433824%A total of 35 overall events were reported in 20 of 43 subjects (46.5%). The most frequently reported event was hypotension which was reported in 11.6% of subjects (5 reports in 5 of 43 subjects).Strengths: Lessons learned on requesting for long term follow-up consent at tiem of IDE enrollmentWeaknesses: Extremely low follow-up of the cohort.No labeling changes were recommended.The study was terminated early due a low follow-up rate
P040040/ PAS002Abbott MedicalAMPLATZER MUSCULAR VSD OCCLUDERCardiovascular2007-09-07Post Approval Study2007-09-072016-03-18Progress InadequateSubject enrollment milestones not metProspective & Retrospective StudyFalseNew Data CollectionHistorical ControlAnalyticalInfant: 29 days-2 yrs; Child: 2-12 yrs; Adolescent: 13-18 yrs; Transit. Adolescent A (distinctively) : 18-21 yrs; Transit. Adolescent B (as adults) : 18-21 yrs; Adult: >21; All Pediatric Patients: 0-21 yrsThis study is a prospective; non-randomized; multi-site clinical study. The primary safety objective is to evaluate the proportion of subjects experiencing a major (serious) adverse event within 12 months of the procedure. The effectiveness objective is to evaluate the proportion of subjects whom experience technical success; closure success; and acute procedure success.This device is indicated for use in patients with a complex VSD of significant size to warrant closure (large volume left to right shunt; pulmonary hypertension and or clinical symptoms of congestive heart failure) who are considered to be at high risk for standard transatrial or transarterial surgical closure based on anatomical conditions and or based on overall medical condition. Eligible patients can be enrolled retrospectively.The comparison group is the Historical Control.One hundred (100) subjects will be enrolled at up to 50 U.S. sites and additional sites in Europe and Canada.If subject follow-up drops below 80%; additional subjects will be enrolled to ensure a final population of 80 subjects either meet a defined endpoint or are followed for five years.Primary safety endpoint:Any major (serious) adverse event within 12 months of the procedure. A serious adverse event is defined as any untoward medical occurrence that: results in death; is a life-threatening adverse event; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a medically significant event.Primary effectiveness endpoints: Technical Success Acute Procedure Success Shunt Closure Success at 12 monthsEach study subject receiving a device will be followed for 60 months post-procedure; unless the device is explanted. Follow-up assessments will be conducted at 30 days; 6 months ; one year; and annually until the five-year visit is complete. If the delivery system enters the subject’s body in an attempt to place a device but no device is implanted during the initial procedure; the subject will be discontinued from the study after a 30-day adverse event collection period.If the device explant occurs before the 12-month visit and a SAE is associated with the device explant; the subject will be discontinued on the date the device is explanted. (In this case; the subject is considered a failure for all endpoints except Technical Success.)If a device explant is not associated with a SAE; the subject will continue to be followed through the 12-month visit. The subject will then be discontinued at the 12-month visit. If a subject has a device explanted after the 12-month visit; the subject will be discontinued on the date of the explant procedure.
P020024 S052 / PAS001Abbott MedicalAMPLATZER Piccolo OccluderCardiovascular2019-01-11Continued FU of IDE/CAP cohort2019-01-11Progress AdequateProspective Cohort StudyTrueNew Data CollectionNo ControlDescriptiveNeonate: 1-28 days; Infant: 29 days-2 yrs; Child: 2-12 yrs
P100009 S028 / PAS001ABBOTT VASCULAR INC.MitraClip NT Clip Delivery System and MitraClip NTR/XTR Clip Delivery SystemCardiovascular2019-03-14Cont f/u of the COAPT Trival Pivotal CohortProgress AdequateProspective Cohort StudyTrueNew Data CollectionConcurrent ControlDescriptiveAdult: >21Continued follow-up of all living subjects who were enrolled in the COAPT Trial pivotal cohort. The objective of this PAS is to characterize the clinical outcomes annually through 5 years post-procedure.All living subjects who were enrolled in the IDE pivotal cohort.All living subjectsThe key safety and effectiveness endpoints include all-cause mortality; stroke; single leaflet device attachment; device embolization; endocarditis requiring surgery; Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery; heart failure (HF) related hospitalization; New York Heart Association (NYHA) classification; 6-Minute Walk Distance (6MWD) through 2 years; Kansas City Cardiomyopathy Questionnaire (KCCQ) score through 2 years; 36-Item Short Form Survey (SF-36) score through 2 years; mitral valve surgery (including type of surgery); new use of Cardiac Resynchronization Therapy (CRT); new use of single or dual chamber pacemaker; permanent left ventricular assist device (LVAD) implant; heart transplant; additional MitraClip device intervention or de novo MitraClip device intervention; including reason for intervention; number of hospitalizations and reason for hospitalization (i.e.; heart failure; cardiovascular; non-cardiovascular) through 2 years; number of days alive and out of hospital; number of days hospitalized; proportion of subjects living in the baseline location; new onset of permanent atrial fibrillation; mitral stenosis; clinically significant atrial septal defect (ASD) that requires intervention; and dosages of guideline directed medical therapy (GDMT).5 years
P100009 S028 / PAS002ABBOTT VASCULAR INC.MitraClip NT Clip Delivery System and MitraClip NTR/XTR Clip Delivery SystemCardiovascular2019-03-14Registry-Based CAP Cohort and RWU Surveillances2019-07-26Progress AdequateComprehensive/Linked/RegistryBased SurveillanceFalseExternal RegistryHistorical ControlDescriptiveAdult: >21Comprehensive/linked/registry-based surveillances. The objectives of the surveillances are to characterize the clinical outcomes of the continued access protocol (CAP) cohort annually through 5 years post-procedure and to assess the real-world use of the commercial MitraClip System to ensure that the device is used in appropriate circumstances.Patients with symptomatic; moderate-to-severe or severe secondary (or functional) mitral regurgitation (MR; MR greater than or equal to Grade III per American Society of Echocardiography criteria) in patients with a left ventricular ejection fraction (LVEF) greater than or equal to 20% and less than or equal to 50%; and a left ventricular end systolic dimension (LVESD) less than or equal to 70 mm whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.All living CAP subjects who were enrolled at participating institutions and a total of 5000 consecutively treated patients at a minimum of 100 representative institutions across the United States.The clinical data through one (1) year will be collected through the TVT Registry. The follow-up data (including all-cause mortality; stroke; repeat procedure for mitral valve-related dysfunction; and hospitalization) from year 2 through year 5 post procedure will be obtained through linking the TVT data with the Centers for Medicare and Medicaid Services (CMS) claims database.5 years
P100009/ PAS002ABBOTT VASCULAR INC.MITRACLIP DELIVERY SYSTEMCardiovascular2013-10-24New EnrollMitraClip Analysis Cohort (MAC)2013-10-242016-04-05CompletedProspective Cohort StudyFalseExternal RegistryObjective Performance CriterionAnalyticalAdult: >21A prospective cohort study; a subset of patients entered into the MitraClip TVT-Registry who fulfill the enrollment criteria and from sites/centers of excellence and experienced with performing and collecting 6MWT data and KCCQ data (i.e. sites/centers with at least 75% completion rate in terms of collecting both 6MWT and KCCQ data) will be included in MAC.This is a new-enrollment study.NOTE: Annual follow up (e.g. death; stroke; surgical intervention; hospitalizations) from year 2 through year 5 post-implant through linkage to the CMS database will be reported as part of P100009/PAS001- OSB-lead Comprehensive/Linked-Registry Based Surveillance. <A HREF="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?t_id=444395&c_id=1705">PAS1</A>A subset of approximately 420 patients entered into the MitraClip TVT-Registry who fulfill the following criteria in MAC: Significant symptomatic MR (? 3+) due to primary abnormality of the mitral apparatus; otherwise known as Degenerative Mitral Regurgitation (DMR). Prohibitive risk for mitral valve surgery (MV) as determined by a heart team; which includes a cardiologist experienced in MV disease and a cardiac surgeon experienced in MV surgery; and existing comorbidities that would not preclude the expected benefit from reduction of the MR. Perform the 6MWT at baseline or unable to perform the 6MWT due to cardiac reasons.No comparator group.Assuming 10% withdrawal at 12 months; a sample size of 420patients from the Prohibitive Risk DMR Patient Registry (PAS 1Device Registry) is expected to provide 420 evaluable patients (notlost-to-follow-up or discontinued) at 12 months post procedure.Assumptions: The reported death rate at 30 days was 6.3% in the Prohibitive Risk DMR Cohort (Lim et al 2013); the all-cause mortality rate at 30 days was assumed to be 6.5%. The device- related complication rate was assumed to be ~6% at 12 months.Because a majority of device-related complications are expected to occur within 30 days of the MitraClip procedure; the rate at 30days was also assumed to be ~6%. Two thousand (2;000) simulations were performed to calculate sample size and power for the primary safety endpoint. A sample size of 420 evaluable patients provides >95% power to reject the null hypothesis at the5% significance level.Two thousand (2;000) simulations were performed to calculate sample size and power for the primary effectiveness endpoint. Assuming 37% attrition (25% death; 10% withdrawal; and 2% missing data) at 12 months; a sample size of 420 evaluable patients provides >95% power to reject the null hypothesis at the 5% significance level.There will be a minimum of 15 sites and a maximum of 40 sites; with no more than 10% of patients (up to 46) from each site. Sites selected for participation in this study will be centers of excellence and experienced with performing and collecting 6MWT data and KCCQ data.Main safety endpoints:A composite of death and device-related complications at 30 dayspost-procedure. The device-related complications include single leaflet device attachment (SLDA); device embolization; device thrombosis; and other device-related events (e.g.; endocarditis; MV stenosis); which result in MV re-intervention; unplanned other cardiac surgery; or unplanned vascular surgery or intervention through 30 days post-procedure.Secondary safety endpoints:All-cause mortality at 12 months; and device-related complications at 12 months.Main effectiveness endpoints:The change in 6MWT distance at 12 months over baseline.Secondary effectiveness endpoints: MR severity at 12 months Change in LVEDV at 12 months over baseline Change in LVIDd at 12 months over baseline Change in KCCQ QoL at 12 months over baselineNYHA Functional Class at 12 Months5 yearsActive follow-up of patients will be performed through 12 months A total 554 study subjects who entered into STS/ACC Transcatheter Valve Therapy (TVT) registry between November 04; 2013 and July 29; 2015 and met eligibility criteria for this study were enrolled in this post-approval study.A total of 50 sites (sites with at least 75% data completeness of both baseline 6-minute walking test and KCCQ data) were included in this post-approval study.The overall follow-up rate at 1-year through the Mitral Module of the TVT registry is 78.2%.The primary safety endpoint of rate of freedom from composite of death and device-related complications at 30 days was 95.5% (529/554); which was significantly higher than the pre-specified performance goal of 80% (P<0.0001). For secondary safety endpoints; freedom from all-cause mortality at 12 months was 80.2% (SE: 1.85%; performance goal=66%; P<0.0001); and freedom from the composite device-related complications at 12 months was 98.9% (SE: 0.45%; performance goal=90%; P<0.0001). All primary and secondary safety endpoints were successfully met.The primary effectiveness endpoint of mean improvement in 6-minute walking test (6MWT) at 12 months from baseline was 31.56±115.24 meters. The results showed significantly improvement at 12 months (one-sided p-value=0.0001). Analysis of secondary effectiveness endpoints shows significant mitral regurgitation (MR) reduction (P<0.0001) and improvement in NYHA class (P<0.0001) at 12-months from baseline; reduction in left ventricular size at 12-months from baseline as per LVEDV (-10.9 ± 48.9 ml; P=0.0111) and LVIDd (-0.22±0.72 cm; P<0.0001) measurements as well as improvement of Kansas City Cardiomyopathy Questionnaire (KCCQ) score at 12 months over baseline (30.40±25.77; P<0.0001).Strength: This study was able to demonstrate the safety and effectiveness of Mitral Valve Repair and Clip Delivery Systems (MitraClip®) using real-world data collected through the national STS/ACC TVT Registry.Weakness: Sample size for some of the subgroup analyses; such as recurrent mitral regurgitationsubgroup; was relatively small; resulting in large standard deviations for the estimates. Although primary effectiveness endpoint was successfully met; only about 62.1% patients among those who have completed 12-month visit had 6MWT information available (including patients who performed 6MWT or were unable to perform due to cardiac reasons). High proportion of missing values were also reported for LVEDV endpoint at 12 months (36.8% of patients who completed 12-month have information available). Patients included in this study were enrolled from sites with at least 75% completion rate in terms of collecting both baseline 6MWT and KCCQ data; and results may not be generalizable to patients enrolled from sites with less experience performing and collecting 6MWT and KCCQ data.Finally; the data available are limited to 1-year follow-up currently; additional data on longer term (5- year) safety and effectiveness remain to be assessed.Yes; labeling change recommended to update the device labeling with the final study results.
P100009/ PAS001ABBOTT VASCULAR INC.MITRACLIP DELIVERY SYSTEMCardiovascular2013-10-24Comprehensive/Linked-Registry Based Surv2013-10-242014-06-13Progress AdequateComprehensive/Linked/RegistryBased SurveillanceFalseExternal RegistryConcurrent ControlDescriptiveAdult: >21Objectives: to assess long term safety and effectiveness of theMitraClip device in a broad patient population and to study howprohibitive risk is interpreted in real-world use of the MitraClip device to ensure the device is used in appropriate circumstances.Study design: a prospective; single-arm; multi-center; observational study of a minimum of 2;000 MitraClip patients consecutively entered into the TVT Registry. A new enrollment study.Patients who have been determined to be at prohibitive risk formitral valve surgery by a heart team; and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation; patients treated in accordance with the MitraClip Clip Delivery System labeling; formal protocol- specific inclusion and exclusion criteria will not be used.Cohort A: Patients treated per the MitraClip Clip Delivery System indication approved on October 24; 2013 will comprise Cohort A. Patients will be identified as Cohort A for analyses if the data collected on the eCRFs identify symptomatic DMR &#8805;3+ and at leastone reason for prohibitive risk.Cohort B: patients from the PAS 1 Device Registry who are not included in Cohort A.Subjects: 2;000 MitraClip patients consecutively entered into the TVT Registry.Sites: This study will include all sites participating in the STS/ACCF TVT Registry and trained by Abbott Vascular to implant the MitraClip device.A minimum of 2;000 patients will allow detection of low frequency safety events and provide improved precision for the rates of safety events that have previously been characterized.Primary Safety/Effectiveness Endpoints:The following endpoints will be reported through 1 year follow-upfrom data extracted from the TVT-R:¿ All-cause mortality at 30 days and 1 year¿ Stroke at 30 days and 1 year¿ NYHA Functional Class at 30 days and 1 year¿ Hospitalizations (All-cause and HF-related) at 1 year¿ The echo parameters of MR severity; left ventricular end-diastolic volume (LVEDV) and Left Ventricular Internal Dimension-Diastole (LVIDd) at baseline; 30 days and 1 year in all patients and in the subset of patients who undergo mitral valve (MV) surgery within the first yearThe following endpoints will be reported for years 2 - 5 post-implant by linking data extracted from the TVT Registry to the Center for Medicare and Medicaid Services (CMS) Claims database:¿ All-cause mortality¿ Stroke¿ Hospitalizations (All-cause and HF-related)¿ Surgical interventionsSecondary Safety/Effectiveness Endpoints:Interpretation of the definition of prohibitive risk status incommercial use will also be reported on. Prohibitive risk status willbe audited by a qualified MitraClip Registry Audit Committee Charter (MRAC) that meets quarterly. The composition and the schedule for auditing is described in the MRAC Charter document (received on June 10; 2014).5 yearsDischarge; 30 days; 1 year annually through 5 years